Live from the NIH registry
Studies recruiting near Reno right now
Top 25 of 201 recruiting studies, sorted by proximity — each links to its official registry page
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Diabetic Macular Edema
Phase 2
Interventional 18 participants sought
Sierra Eye Associates — Reno, Nevada (2.3 mi)
· Sponsor: Sierra Eye Associates
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Phase 3
Interventional 400 participants sought
Renown Health Medical Oncology — Reno, Nevada (2.3 mi)
· Sponsor: Pfizer
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Diabetic Retinopathy
Phase 2, Phase 3
Interventional 576 participants sought
Sierra Eye Associates /ID# 274737 — Reno, Nevada (2.3 mi)
· Sponsor: AbbVie
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Acute Migraine
Phase 3
Interventional 1,000 participants sought
Advanced Research Institute-Reno — Reno, Nevada (2.3 mi)
· Sponsor: TriGemX Bio, Inc.
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Phase 3
Interventional 186 participants sought
Center of Hope — Reno, Nevada (2.3 mi)
· Sponsor: Genelux Corporation
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: National Cancer Institute (NCI)
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
Cancer
N/A
Observational 2,400 participants sought
Renown Health — Reno, Nevada (2.3 mi)
· Sponsor: Exai Bio Inc.
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Phase 3
Interventional 1,273 participants sought
Gene Upshaw Memorial Tahoe Forest Cancer Center — Truckee, California (23.5 mi)
· Sponsor: SWOG Cancer Research Network
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Retroperitoneal Sarcoma, Liposarcoma
Phase 3
Interventional 250 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Cigarette Smoking-Related Carcinoma
Phase 3
Interventional 600 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Multiple conditions
Phase 2
Interventional 98 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: NRG Oncology
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Phase 3
Interventional 398 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: NRG Oncology
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
N/A
Interventional 9,500 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: NRG Oncology
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2
Interventional 310 participants sought
Site 0213 - Center of Hope — Reno, Nevada (2.3 mi)
· Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Multiple conditions
N/A
Observational 2,900 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple Negative Breast Cancer
Phase 3
Interventional 1,514 participants sought
Cancer Care & Hematology Specialists — Reno, Nevada (2.3 mi)
· Sponsor: Gilead Sciences
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Renown Health Medical Oncology — Reno, Nevada (2.3 mi)
· Sponsor: Relay Therapeutics, Inc.
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
Complex Regional Pain Syndrome Type I
Phase 3
Interventional 270 participants sought
Ambros Clinical Trial Site — Reno, Nevada (2.3 mi)
· Sponsor: Ambros Therapeutics, Inc.
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
Phase 3
Interventional 741 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: NovoCure GmbH
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Phase 2
Interventional 324 participants sought
Sierra Eye Associates — Reno, Nevada (2.3 mi)
· Sponsor: ONL Therapeutics
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Phase 3
Interventional 274 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: SWOG Cancer Research Network
Supporting Treatment Resilience With Optimized Nutrition and Guided Exercise in Head and Neck Cancer Patients Undergoing Chemoradiation
Head and Neck Cancer
N/A
Interventional 30 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: Renown Health
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: SWOG Cancer Research Network
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Phase 3
Interventional 230 participants sought
Renown Regional Medical Center — Reno, Nevada (2.3 mi)
· Sponsor: Hoffmann-La Roche